RemeGen Co (FRA:REG) ROC (Joel Greenblatt) %: 174.62% (As of Dec. 2025)


FRA:REG RemeGen Co Ltd FRA:REG
39 GF Score
Price €9.36
GF Value €15.26
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is RemeGen Co ROC (Joel Greenblatt) %?

RemeGen Co FRA:REG -2.42% 39 ROC (Joel Greenblatt) % is 174.62% as of Dec. 2025. GuruFocus rates FRA:REG with a GF Score™ of 39/100 and a GF Value™ of €15.26 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,320 Biotechnology companies, RemeGen Co ranks better than 90.76% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. RemeGen Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 174.62%.

The historical rank and industry rank for RemeGen Co's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:REG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -90.59   Med: -43.48   Max: 37.59
Current: 37.59

During the past 8 years, RemeGen Co's highest ROC (Joel Greenblatt) % was 37.59%. The lowest was -90.59%. And the median was -43.48%.

FRA:REG's ROC (Joel Greenblatt) % is ranked better than
90.76% of 1320 companies
in the Biotechnology industry
Industry Median: -294.23 vs FRA:REG: 37.59

RemeGen Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


RemeGen Co  (FRA:REG) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


RemeGen Co ROC (Joel Greenblatt) % Related Terms


RemeGen Co ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for RemeGen Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co ROC (Joel Greenblatt) % Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial 21.16 -42.54 -44.84 -39.67 23.06

RemeGen Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.55 -44.85 0.00 -10.75 174.62

FRA:REG vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, RemeGen Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where RemeGen Co's ROC (Joel Greenblatt) % falls into.


FRA:REG
39GF Score
RemeGen Co Ltd FRA:REG
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(43.295 + 78.65 + 24.043) - (92.911 + 0 + 117.758)
=-64.681

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(51.262 + 80.206 + 16.801) - (113.414 + 0 + 49.368)
=-14.513

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of RemeGen Co for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=618.008/( ( (347.693 + max(-64.681, 0)) + (360.119 + max(-14.513, 0)) )/ 2 )
=618.008/( ( 347.693 + 360.119 )/ 2 )
=618.008/353.906
=174.62 %

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 174.62% mean?
RemeGen Co (FRA:REG) has a ROC (Joel Greenblatt) % of 174.62% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #122 out of 1320 companies in the Biotechnology industry, placing it in the top 9.2%.
Is RemeGen Co's ROC (Joel Greenblatt) % too high?
RemeGen Co's current ROC (Joel Greenblatt) % is 174.62%. Based on the distribution chart, RemeGen Co ranks #122 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RemeGen Co has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #122 out of 1320 companies for ROC (Joel Greenblatt) %. This places RemeGen Co in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on RemeGen Co and its competitors. RemeGen Co's current ROC (Joel Greenblatt) % is 174.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €15.26, compared to a current price of €9.36 — trading 38.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 174.62%. RemeGen Co's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current ROC (Joel Greenblatt) % is 174.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (FRA:REG) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of €9.36 is trading 38.7% below its estimated GF Value™ of €15.26. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for FRA:REG:

  • ROC (Joel Greenblatt) %: 174.62%
  • GF Value™: €15.26 vs. price of €9.36 (38.7% below fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
39GF Score

Get the complete analysis for FRA:REG

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.36
Price
€15.26
GF Value